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Abstract 
Human cytosolic thymidine kinase (hTK1) has proven to be a suitable target for the non-invasive 
imaging of cancer cell proliferation using radiolabelled thymidine analogues such as [18F]3′-fluoro-3′-
deoxythymidine ([18F]FLT).  A thymidine analogue for single photon emission computed tomography 
(SPECT) incorporating the readily available and inexpensive nuclide technetium-99m would be of 
considerable practical interest.  hTK1 is known to accommodate modification of the structure of the 
natural substrate thymidine at the positions, N3, C3′ and, to a lesser extent, C5.  In this work, we used 
the copper catalyzed azide-alkyne cycloaddition to synthesize two series of derivatives in which 
thymidine is functionalized at either the C3′ or N3 position with chelating systems suitable for the 
M(CO)3 core (M = 99mTc, Re).  The click chemistry approach enabled complexes with different 
structures and overall charges to be synthesized from a common precursor.  Using this strategy, the 
first organometallic hTK1 substrates in which thymidine is modified at the C3′ position were 
identified.  Phosphorylation of the organometallic derivatives was measured relative to thymidine.  
We have shown that the influence of the overall charge of the derivatives is dependent on the position 
of functionalization.  In the case of the C3′-functionalized derivatives, neutral and anionic substrates 
were most readily phosphorylated (20-28% of the value for the parent ligand thymidine), whereas for 
the N3-functionalized derivatives, cationic and neutral complexes were apparently better substrates 
for the enzyme (14-18%) than anionic derivatives (9%). 
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Introduction 
Human thymidine kinase 1 (hTK11) is a cytosolic enzyme which catalyzes the -phosphate transfer 
from ATP to the 5′-hydroxyl groups of thymidine (dT) and 2′-deoxyuridine (dUrd).  Other hTK1 
substrates include 3′-azido-3′-deoxythymdine, AZT and 3′-fluoro-3′-deoxythymidine, FLT, where 
thymidine has been modified at the C3′-position, and the phosphorylation of which is the first step in 
their activation as anti-HIV prodrugs.(1, 2)  It is well documented, however, that hTK1 is among the 
most selective of the nucleoside kinases, and is particularly sensitive to changes in the structure of the 
natural substrates dT and dUrd.(3)  Eriksson et al. have shown that minor modification of the 
structure at the 5-position is possible, for example, 5-halo and 5-ethyl substitutions are tolerated, but 
substitution with bulkier groups such as 5-propenyl or 5-(2-chloroethyl) are not.(1, 4)  More recently, 
Tjarks and co-workers have shown that hTK1 is also amenable to modification of thymidine at the 
N3-position.(5, 6)  Functionalization with a series of bulky carborane derivatives, tethered from N3 of 
the pyrimidine base with varying spacer length, does not prevent phosphorylation of the nucleoside 
analogue.  The experimental results of substrate activity investigations have all since been rationalized 
by the determination of the 3-D structure of hTK1, which confirms that hTK1 has a much smaller 
binding site than other nucleoside kinases.(7) 
Unlike the activity of other mammalian deoxyribonucleoside kinases, hTK1 activity is stringently cell 
cycle regulated.(3)  Active enzyme is not found in resting cells, but activity increases dramatically by 
the time cells reach the S-phase, to coincide with DNA synthesis.  A number of thymidine analogues, 
which aim to target the high hTK1 activity in proliferating cells, have been developed.  As potential 
agents for boron neutron capture therapy, thymidine derivatives incorporating closo-o- and nido-m-
carboranes have been extensively investigated.(5, 6, 8, 9)  Similarly, thymidine derivatives labelled 
with radionuclides suitable for positron emission tomography (PET) have been developed with the 
goal of monitoring tumour growth and response to therapy.(10-12)  However, PET nuclides typically 
have very short half-lives and their production is expensive, usually requiring an onsite cyclotron.  A 
thymidine analogue labelled with technetium for in vivo single photon emission computed 
tomography (SPECT) would be of considerable interest.  Technetium has near perfect decay 
                                                             
1 Abbreviations: hTK1, human thymidine kinase 1; ATP, adenosine triphosphate; dT, thymidine; dUrd, uridine; 
AZT, 3′-azido-3′-deoxythymdine; FLT, 3′-fluoro-3′-deoxythymdine; PET, positron emission tomography; 
SPECT, single photon emission tomography; TBDMS, tertiary-butyldimethylsilyl; Boc, tertiary-
butoxycarbonyl; dTTP, thymidine 5'-triphosphate; hENT1, human equilibrative nucleoside transporter; IdUrd, 
5-iododeoxyuridine; FdUrd, 5-fluorodeoxyuridine; Glut1, glucose transporter 1; LAT, large neutral amino acid 
transporter 1; PBS, phosphate buffered saline; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 
NADH, nicotinamide adenine dinucleotide hydrate; PK, pyruvate kinase; LDH, lactate dehydrogenase; DTT, 
dithiothreitol; PEP, phospho(enol)pyruvate. 
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characteristics for diagnostic applications (T1/2 = 6 h, 140 keV γ-radiation), moreover it is readily 
available at low cost from a 99Mo/99mTc generator system. 
Given the promising reports of the retained substrate activity of N3-functionalized carborane 
thymidine derivatives,(5, 6, 9) the N3 position is appealing for functionalization with a technetium 
complex.  We recently reported the synthesis and in vitro evaluation of two series of technetium-
labelled thymidine derivatives in which the nucleoside was functionalized at the N3 position, and 
could qualitatively show that all of the compounds retained activity towards hTK1.(13, 14)  It has also 
been reported, that minor structural modifications at the C3′ position do not dramatically lower 
affinity towards hTK1.(4)  From the elucidation of the structure of hTK1, Welin et al. suggest that 
tolerance of C3′ modification could be a result of the open nature of the C3′/C4′ environment and the 
proximity of the C3′ substituent to the surface of the enzyme.(7)  However, to our knowledge there 
have not been any systematic investigations into the steric tolerance of hTK1 at this position.  Tjarks’ 
group report a small series of compounds in which thymidine has been functionalized at the 3′ 
position with a carborane.(15)  Unfortunately the low stability of these compounds prevented their 
thorough characterization with respect to their activity towards hTK1. 
The aim of the current investigation was the synthesis of technetium-labelled thymidine analogues, 
which have the potential to be used in radiopharmacy as proliferation markers.  We chose to 
investigate the substrate activity of C3′-functionalized thymidine analogues, and to compare these 
with N3-functionalized derivatives, particularly with regard to their overall charge.  We used the 
“click-to-chelate” approach(14, 16) for the parallel synthesis of two series of derivatives which could 
be labelled with technetium and rhenium (Figure 1).  This strategy exploits the remarkable features of 
the copper catalyzed azide-alkyne cycloaddition(17, 18) and enables simultaneous formation of the 
chelating system and conjugation to a biologically relevant molecule in a single, high-yielding step.  
In the present study a series of bidentate alkynes (Figure 1, 2-6) were reacted with either the 
commercial C3′-azido thymidine derivative AZT (C3′dT-N3) or an N3 azido-thymidine derivative 
(N3dT-N3, 1) to yield two sets of conjugates with efficient tridentate triazole-containing chelators for 
the M(CO)3 core (M = 99mTc, Re).  This enabled us to identify novel organometallic substrates for 
hTK1 and qualitatively analyze structure-activity relationships.  Preliminary investigations were also 
carried out into the cell-internalizing ability of representative complexes in two human glioblastoma 
cell lines. 
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Figure 1.  General reaction scheme: alkyne derivatives 2-6 are reacted with C3′ and N3 functionalized azido-
thymidine derivatives to give conjugates with tridentate chelating systems, which can be labelled with the 
M(CO)3 core (M = 99mTc, Re). 
 
Results and discussion 
Chemistry 
Thymidine can be readily functionalized at the C3′ position using the “click-to-chelate” approach 
starting from the commercially available azide 3′-azido-3′-deoxythymidine, AZT.  Tridentate 
chelators for the M(CO)3 core were incorporated by reaction of AZT with a suitable alkyne (Scheme 
1).  Suitable alkynes (Figure 1) were prepared by alkylation of propargylamine with bromoacetate (5), 
alkylation of commercial amines with propargyl bromide (3 and 6), or are commercially available (2 
and 4).  Full details of the synthesis of the alkyne components used were recently reported.(14)  The 
copper catalyzed azide-alkyne cycloaddition was performed using standard Sharpless conditions: one 
equivalent of alkyne and one equivalent of azide were stirred at room temperature for 12 hours in a 
mixture of tBuOH and water with catalytic amounts of copper acetate (0.1 equivalents) and sodium 
ascorbate (0.2 equivalents).(19)  For ease of purification of the products, alkynes 2-5 were substituted 
with compounds 2a-5a, in which carboxylic acids were protected as methyl esters and primary amines 
were Boc-protected.  However, in previous studies we have shown that for radiolabelling purposes it 
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is not necessary to use protected substrates, or indeed to purify the ligands prior to radiolabelling.(14, 
16) 
Thymidine derivatives 7 and 8 were prepared from the reactions of AZT with alkynes 2a and 3a, 
respectively.  In both cases the Boc-protected triazole products were purified by silica gel 
chromatography using mixtures of CH2Cl2 and MeOH before the Boc protecting groups were 
removed in a mixture of trifluoroacetic acid (10%) and CH2Cl2.  Compounds 7 and 8 were purified by 
solid phase extraction using Sep-Pak® columns.  Thymidine derivatives 9 and 10 were prepared from 
the reactions of AZT with alkynes 4a and 5a, respectively.  The intermediates were purified by silica 
gel chromatography before the methyl esters were removed with aqueous NaOH.  Compounds 9 and 
10 were purified by solid phase extraction using Sep-Pak® columns.  Compound 11 was purified by 
silica gel chromatography after the reaction of AZT and N-propargyl-pyridine-2-methylamine, 6. 
Scheme 1.  Synthesis of C3′-functionalized thymidine derivativesa 
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a (a) Cu(OAc)2.H2O, Na(ascorbate), tBuOH/H2O (b) TFA, CH2Cl2 (c) NaOH, H2O, followed by HCl. 
The N3-functionalized thymidine derivatives 12, 13, 15 and 16 have been reported previously, 
however, they were only characterized via mass spectrometry.(14) For their synthesis, thymidine was 
functionalized at the N3 position with an azido-ethyl group following the recently reported 
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procedure.(14, 20)  In analogous procedures to the synthesis of the C3′-functionalized derivatives 
described above, tridentate chelators for the M(CO)3 core (M = 99mTc, Re) were installed at the N3 
position by reacting the N3-functionalized azido-thymidine derivative 1 or the O-TBDMS protected 
precursor 1a with alkynes 2-6 using standard conditions for the click reaction and as outlined in 
Scheme 2.  Thymidine derivatives 12 and 13 were prepared from the reactions of the O-TBDMS 
protected N3-functionalized thymidine precursor, 1a, and alkynes 2a and 3a, respectively.  The 
protected triazole intermediates were purified by silica gel chromatography using mixtures of CH2Cl2 
and MeOH.  In both cases the Boc and TBDMS protecting groups of the products were removed in a 
single step with HCl in MeOH.  Compounds 12 and 13 were purified by solid phase extraction, 
although compound 12 could also be recrystallized from MeOH.  Similarly, derivative 14 was 
prepared from the reaction of 1a with alkyne 4a.  The protected intermediate was stirred in 
HCl/MeOH to remove the TBDMS protecting groups, followed by aqueous NaOH to remove the 
methyl esters.  Thymidine derivative 15 was prepared from the reaction of 1 and alkyne 5a.  The 
intermediate was purified by silica gel chromatography before the methyl ester was removed with 
aqueous NaOH.  In this case, removal of the TBDMS protecting groups from the azido-thymidine 
derivative 1a with NBu4F proved more efficient before the click reaction, as 1 could more easily be 
separated from excess NBu4+ salts than the more hydrophilic triazole product 15.  Both compounds 14 
and 15 were purified by solid phase extraction using Sep-Pak® columns.  Compound 16 was purified 
by silica gel chromatography after the reaction of 1 and N-propargyl-pyridine-2-methylamine, 6. 
Scheme 2.  Incorporation of tridentate chelators into N3-functionalized thymidinea 
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a (a) Cu(OAc)2.H2O, Na(ascorbate), tBuOH/H2O (b) HCl, MeOH (c) NaOH, H2O, followed by HCl.  
The Re(CO)3 complexes of all of the functionalized thymidine derivatives were prepared from the 
precursor [ReBr3(CO)3][NEt4]2 and a stoichiometric amount of the corresponding ligand in a mixture 
of MeOH and water at 50 °C.  In each case the quantitative formation of the product was observed by 
HPLC.  The crude products were purified by solid phase extraction using SepPak® columns and a 
water-MeOH gradient.  The IR spectra of all of the rhenium complexes revealed the typical fac-
Re(CO)3 pattern with significantly blue-shifted, intense CO stretching frequencies (around 2020 cm-1 
and 1880 cm-1) compared with the starting material [ReBr3(CO)3]2- (2000 cm-1 and 1868 cm-1).  NMR 
analyses provided evidence that in each case the metal core is site-specifically coordinated to the 
tridentate metal chelating system introduced at either the C3′ or N3 position, and showed similar 
features to model complexes which were synthesized with benzyl azide and characterized 
previously.(14)  Typically, the proton NMR spectra showed low field shifts of the protons in the 
chelating system after metal chelation.  Independent resonances are observed for each proton in the 
CH2 groups of the chelating system; they become distinguishable due to a lack of symmetry in the 
metal chelate.  As was the case with the model complexes, signals for the protons of coordinated 
primary and secondary amines were also observed in the NMR spectra of the thymidine complexes as 
a result of the decrease in rate of H/D exchange.  A key difference between the thymidine chelates and 
the analogous model complexes is the appearance of diastereoisomers, which can be distinguished in 
some cases by NMR and/or HPLC.  For the C3′ complexes HPLC analyses revealed two isomeric 
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products for both [Re(CO)38]Br and [Re(CO)310], but only in the case of [Re(CO)311]Br were two 
isomers apparent in the 1H NMR spectrum.  For the N3-functionalized complexes [Re(CO)313/16]Br, 
and [Re(CO)315], two diastereoisomers can be distinguished by NMR.  The differences in chemical 
shifts of the two isomers are most pronounced for the complex [Re(CO)313]Br, and HPLC analysis 
also revealed two product peaks in this case.  In analogous model complexes, where a benzyl group 
substitutes the thymidine residue, isomers were not distinguishable by either HPLC or NMR.(14)  All 
of the complexes were readily water soluble, which is a prerequisite for in vitro assessment. 
Crystals of the complex [Re(CO)311][CF3CO2] suitable for x-ray crystallography were prepared by 
exchange of the bromide anion with the more bulky CF3CO2- anion using the corresponding silver 
salt.  The final crystals were grown by diffusion of diethyl ether into a solution of the complex in 
methanol.  Structural analysis revealed that the counter ion was a mixture of Br- and CF3CO2- as a 
result of incomplete precipitation of AgBr.  The structure of the complex cation confirmed the 
expected tridentate, facial coordination of the κN,κN,κN chelator, which has not previously been 
structurally characterized (Figure 2).  The Re-N3 bond length (2.146 (3) Å) is in agreement with the 
Re-N(triazole) bond length in other Re(CO)3 complexes with triazole containing ligands.(14)  
Similarly the Re-N4 (2.218(4) Å) and Re-N5 (2.181(3) Å) bond lengths are consistent with those 
found in Re(CO)3 complexes with amine and pyridine containing chelators.(21-23)  For example, 
Banerjee et al. report the crystallographic characterization of a series of tridentate chelating systems 
for the M(CO)3 core (M = 99mTc, Re) which incorporate an aliphatic amine with pyridyl and/or 
imidazoyl donor groups and are structurally similar to the chelator in compound 11.(21)  The Re-N 
bond lengths in the novel triazole-containing chelating system were consistent with the values 
reported for the coordinated aliphatic amines (2.23-2.29 Å), pyridyl (2.16-2.18 Å) and imidazoyl 
(2.14-2.16 Å) groups.  Crystallographic data are reported in the supporting information. 
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Figure 2.  ORTEP-3(24) representation of the complex cation [Re(CO)311]+ with thermal ellipsoids shown at 
50% probability.  Hydrogen atoms are omitted for clarity.  Selected bond lengths [Å] and angles [°]: Re(1)-N(3) 
2.146(3), Re(1)-N(4) 2.218(4), Re(1)-C(31) 1.915(4), Re(1)-C(32) 1.929(5), Re(1)-N(5) 2.181(3), Re(1)-C(33) 
1.900(5), C(33)-Re(1)-C(31) 91.46(18), C(33)-Re(1)-C(32) 88.3(2), C(31)-Re(1)-C(32) 87.17(19), C(32)-Re(1)-
N(3) 172.83(16), C(31)-Re(1)-N(5) 171.65(19), C(33)-Re(1)-N(4) 170.51(16). 
Radioactive technetium-99m complexes were prepared with the ligands 7, 8, 10, 11, 12, 13, 15 and 
16.  The complexes were prepared quantitatively by adding the organometallic precursor 
[99mTc(CO)3(H2O)3]+(25) to a solution of the ligand in physiological phosphate buffer (PBS; pH 7.4) 
and heating for 45 minutes at 95 °C.  In each case a single product was observed.  Characterization of 
the radioactive complexes was accomplished by comparison of the retention times observed in the γ-
HPLC trace with those in the UV-trace of the corresponding rhenium complexes.  Given the 
experimental limitations, the retention times matched for all pairs of complexes.  For in vitro and 
enzymatic studies 99mTc complexes were separated from unreacted thymidine derivatives by HPLC. 
In vitro evaluation of the organometallic thymidine derivatives 
Substrate activity toward human thymidine kinase.  We have shown previously that the 99mTc-labelled 
complexes [99mTc(CO)312] and [99mTc(CO)313] are substrates for hTK1, by incubating a solutions of 
the complexes ATP in the presence of hTK1.  Under the same conditions, substrate activity was not 
observed with the complexes [99mTc(CO)315]+ and [99mTc(CO)316]+.(14)  In the current investigation, 
the hTK1 substrate activities of all target rhenium complexes were assessed using a coupled 
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thymidine kinase-pyruvate kinase-lactate dehydrogenase UV assay (λ = 340 nm) as previously 
described.(6, 26)  We were able to show that all of the C3′-functionalized and N3-functionalized 
rhenium complexes were substrates for hTK1 (Scheme 3).  The results with both series of compounds 
are presented in Table 1.  The phosphorylation of thymidine was arbitrarily set to 100%. 
Scheme 3.  Phosphorylation of C3′ and N3 functionalized 99mTc/Re(CO)3-labelled thymidine 
derivatives. 
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In the first series of complexes the ribose of thymidine is functionalized directly at the C3′ position 
and there is no spacer between the thymidine and metal chelate.  The metal-labelled compounds have 
varying overall charges depending on the functional groups of the chelating system.  The relative rates 
of phosphorylation ranged from 13-28%.  The neutral complex [Re(CO)310] had the highest relative 
phosphorylation of 27.6 ± 1.9%.  There is a clear trend in phosphorylation rate as a function of overall 
charge.  The anionic C3′-functionalized compound (23.1 ± 1.8%) has a comparable rate of 
phosphorylation to the neutral C3′-functionalized compounds (27.6 ± 1.9% and 20.3 ± 0.8%), whereas 
the cationic complexes appear to be much less readily phosphorylated (12.5 ± 0.5% and 14.2 ± 0.2% 
for [Re(CO)38]Br and [Re(CO)311]Br, respectively).  This is perhaps surprising given that the 
structure of hTK1 co-crystallized with the feedback inhibitor thymidine triphosphate (dTTP) shows 
the proximity and suspected interaction of the C3′ substituent (in the case of dTTP, a hydroxyl group) 
with a glycine residue and an aspartic acid residue.(7)  There is, however, an arginine residue in the 
same region of the active site.  Interaction between the C3′ substituent and the cationic side chain of 
arginine may compensate for the loss of interaction with the C3′ hydroxyl group of thymidine, and 
thus be an explanation for the greater substrate efficiency of the anionic complex compared to the 
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cationic complexes.  However, at the moment this remains purely speculative and only co-
crystallization of the complex with the enzyme would provide further insight into the observed trend. 
Table 1.  Phosphorylation of organometallic thymidine complexes [Re(CO)37-16]. 
Compound 
Position of 
functionalization 
Overall charge Phosphorylation [%]a 
[Re(CO)37] C3′ Neutral 20.3 ± 0.8 
[Re(CO)310] C3′ Neutral 27.6 ± 1.9 
[Re(CO)39]NEt4 C3′ Anionic 23.1 ± 1.8 
[Re(CO)38]Br C3′ Cationic 12.5 ± 0.5 
[Re(CO)311]Br C3′ Cationic 14.2 ± 0.2 
[Re(CO)312] N3 Neutral 17.9 ± 0.1 
[Re(CO)315] N3 Neutral 14.1 ± 0.2 
[Re(CO)314]NEt4 N3 Anionic 9.0 ± 0.4 
[Re(CO)313]Br N3 Cationic 10.9 ± 0.4 
[Re(CO)316]Br N3 Cationic 16.8 ± 0.2 
Thymidine - - 100a 
a The phosphroylation of thymidine was arbitrarily set to 100%. 
In the second series of compounds, thymidine was functionalized at the N3 position.  As for the C3′-
functionalized complexes the overall charges of the derivatives vary, but in all cases there is an ethyl 
spacer between thymidine and the metal complex.  The phosphorylation data show that in general the 
C3′-functionalized compounds are better substrates for hTK1 than the N3-functionalized compounds.  
The phosphorylation is relatively low compared to thymidine for all of the complexes (9-18%), 
although interestingly in this series of compounds the neutral and cationic complexes appear to be 
better substrates than the anionic complex.  This is consistent with results from Tjarks et al., which 
show that zwitterionic NH3+-nido-m-carborane-substituted thymidine analogues (with a propyl spacer) 
have high substrate activity.(27)  However, the variation in the phosphorylation of the two cationic 
complexes (10.9 ± 0.4% and 16.8 ± 0.2% for [Re(CO)313]Br and [Re(CO)316]Br, respectively), 
suggests that in addition to overall charge, structural differences in the metal chelate also affect the 
substrate affinity for hTK1.  It is not possible, therefore, to rule out structural differences in addition 
to overall charge as the reason for the lower substrate affinity of the complex [Re(CO)314]NEt4, 
which in contrast to the anionic C3′-functionalized compound, had the lowest phosphorylation rate in 
the series (9.0 ± 0.4%). 
In a second, direct assay the radioactive and non-radioactive complexes [99mTc/Re(CO)3X] (X = 7, 10, 
11, 15) were incubated with ATP and recombinant hTK1 only.  The enzymatic reactions were 
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analysed by HPLC (UV-trace at λ = 254 nm for the rhenium complexes, γ-trace in the case of the 
radioactive Tc-99m complexes).  For both the 99mTc and the Re compounds phosphorylation resulted 
in a measurable shift in retention time on a C18 reversed phase column and the monophosphorylated 
products [99mTc/Re(CO)3X]-P (X = 7, 10, 11, 15) were distinguished clearly from the starting 
material.  In the case of the complex [Re(CO)37], the reaction mixture was purified by HPLC, and the 
fractions collected were analysed by mass spectroscopy.  The fraction corresponding to the starting 
material showed a mass peak at m/z = 651.09, [C18H19N6O9Re]H+.  The more hydrophilic 
phosphorylated complex, [Re(CO)37]-P, revealed a mass peak at m/z = 731.03 [C18H20N6O12PRe]H+.  
In time dependent HPLC experiments monitoring the phosphorylation of complex [Re(CO)37], an 
increase in the concentration of the monophosphorylated species, [Re(CO)37]-P, and corresponding 
decrease in the concentration of the starting complex was observed. 
Cell internalization experiments.  hTK1 is located in the cytosol, and therefore a potential substrate 
has to pass through the cell membrane before it can be phosphorylated.  If this transport is not 
achieved actively via nucleoside transporters then it must occur by passive diffusion.(28)  This has 
been suggested as the major cell internalization route for the carborane-thymidine derivatives reported 
by Tjarks et al.(27)  Similarly, AZT is not recognized by the ubiquitously expressed human 
equilibrative nucleoside transporter type 1 (hENT1) and is transported primarily by passive 
diffusion.(29) By analogy to the N3-functionalized carborane derivatives and AZT, we suspected 
passive diffusion would be the most likely cell internalization route of our C3′/N3-functionalized 
complexes. 
In a preliminary study of the cell internalizing ability of the organometallic thymidine derivatives, we 
investigated the internalization of one 99mTc(CO)3-labelled complex from each series of compounds.  
We expected the neutral complexes to be the most likely to be internalized based on our previous 
experience.(13)  We therefore chose to investigate the neutral complex [99mTc(CO)37] from the series 
of C3′-functionalized compounds.  To complete a previous series of N3-functionalized thymidine 
analogues, we chose to investigate the cationic complex [99mTc(CO)316]+, (internalization of anionic 
and neutral N3-functionalized thymidine analogues has been observed previously).(13)  The 
incorporation of both complexes into two human glioblastoma cell lines was measured and compared 
with the incorporation of 125I-iododeoxyuridine (125IdUrd), using cell lines and conditions established 
for the incorporation of 125IdUrd.(30, 31)  Internalization was measured with and without pretreatment 
with 5-fluorodeoxyuridine (FdUrd), which is known to increase uptake of 5-iododeoxyuridine by 
inhibiting endogenous thymidine synthesis and inducing upregulation of nucleoside transporters.(30, 
32-34)  The results for both cell lines, U251 and LN229, and with and without 5-fluorodeoxyuridine 
pretreatment are presented in Table 2. 
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Table 2. Internalization into the human glioblastoma cell lines U251 and LN229, with and without pretreatment 
with 5-fluorodeoxyuridine, as a percentage of the initial activity added. 
 U251 LN229 
 Internalization [%] 
Pretreated with 
FdUrda [%] 
Internalization [%] 
Pretreated with 
FdUrda [%] 
125IdUrd 14.03 ± 1.69 59.29 ± 2.80 8.81 ± 0.43 39.40 ± 1.39 
[99mTc(CO)37] 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
[99mTc(CO)316]+ 0.13 ± 0.01 0.14 ± 0.01 0.12 ± 0.01 0.15 ± 0.01 
a Cells were incubated with 1 µM FdUrd for 1 hour before addition of the radioactive dT analogue. 
The data show that there was only minor cell-associated radioactivity after incubation of both cell line 
with [99mTc(CO)37] and [99mTc(CO)316]+.  This can be rationalized either as a lack of uptake, or as a 
lack of intracellular retention of the radioactive probes.  Assuming that the complexes are stable in 
vitro and are intracellularly phosphorylated, the data suggest that neither of the 99mTc-labelled 
derivatives are able to enter the cells.  This is further corroborated by the fact that pretreatment with 5-
fluorodeoxyuridine (FdUrd), which should stimulate nucleoside transport, had no effect on the 
amount of radioactivity associated with the cells, further evidence that uptake is not mediated by 
nucleoside transporters.  It is likely that the structural modification at either the C3’ or the N3 position 
is significant enough to prohibit active incorporation mediated by nucleoside transporters.  This is in 
agreement with our previous experience of organometallic thymidine derivates.  Although we 
reported moderate cell uptake of N3-functionalized thymidine derivatives (0.6-4.8%) into SKNMC 
tumour cells, uptake increased with increasing lipophilicity.(13)  We assume, therefore, that factors 
such as hydrophilicity, charge and/or size prevent [99mTc(CO)37] or [99mTc(CO)316]+ exhibiting any 
significant internalization via passive diffusion.  An alternative explanation for the negligible 
accumulation of radioactivity is that either the compounds are not sufficiently effectively 
phosphorylated, or that they are susceptible to intracellular degradation.  It has been shown for a 
number of N3-functionalized carboranyl thymidine analogues that the compounds cannot compete 
intracellularly with thymidine and therefore are not effectively phosphorylated.(35) 
 
Conclusions 
Starting from two azido-functionalized thymidine derivatives, we were able to investigate the 
influence of the position of the metal complex on the substrate affinity, as well as the influence of 
charge on the relative phosporylation of two series of novel M(CO)3-labelled thymidine derivatives.  
The “click-to-chelate” approach was used to synthesize thymidine derivatives functionalized with a 
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tridentate chelator for the M(CO)3 core (M = 99mTc, Re) at either the C3′ or N3 position of thymidine.  
All of the conjugates could be readily labelled with the M(CO)3 precursors to form well-defined 
organometallic complexes, with differing structures and overall charges.  Incubation of the Re(CO)3 
derivatives with ATP in the presence of hTK1 led to the formation of monophosphorylated 
organometallic thymidine derivatives, which were observed by HPLC and unambiguously identified 
by mass spectroscopy.  In this way, we were able to show that all of the compounds tested, which 
vary in the position of the metal chelate and overall charge, were substrates for hTK1.  For each of the 
complexes the rate of phosphorylation was measured quantitatively relative to thymidine, the natural 
substrate for hTK1.  We could show that for the two sets of compounds investigated the C3′-
functionalized thymidine derivatives were on average more readily phosphorylated by hTK1 than the 
N3-functionalized derivatives.  Furthermore, we have shown that the effect of the overall charge of 
the substrate is dependent on the position of the metal complex.  For the C3′-functionalized 
complexes, the rates of phosphorylation followed the trend neutral ≈ anionic > cationic.  In the case of 
the N3-functionalized derivatives the trend neutral ≈ cationic > anionic was observed for the relative 
phosphorylation rates of the complexes. 
The first cell internalization experiments did not give promising results.  Neither of the C3′ or N3 
functionalized derivatives tested were either actively or passively transported into cells.  It seems 
unlikely that any of the current set of compounds will be useful as a proliferation marker.  The 
incorporation of, for example, a cell penetrating peptide sequence may improve uptake, however, 
introduction of an additional targeting group would induce further structural changes that in turn 
would decrease the substrate activity of compounds which already show significantly lower activity 
than the natural substrate.  As we have shown and noted before in a similar study of technetium-
labelled glucose analogues, it is possible to develop 99mTc-based, small molecular substrates for a 
given enzyme (such as hexokinase, or in the present case hTK1).  However, a critical point during the 
development of such compounds is their active transport by transporters with further substrate 
specificity (such as Glut1 or a nucleoside transporter) to their intracellular targets.  Although there 
have been recent reports of organometallic pseudo-amino acids which target the LAT transporter,(36) 
in general it would appear that 99mTc and metal-based radiopharmaceuticals which target receptors 
which themselves facilitate internalization show much more promise for the future. 
 
Experimental details 
Chemistry 
15 
 
All chemicals were purchased from Sigma-Aldrich or Fluka, Buchs, Switzerland. All chemicals and 
solvents were of reagent grade and were used without further purification unless otherwise stated.  
The precursor fac-[Re(CO)3Br3][NEt4]2(37) was prepared according to the published procedure.  
[Na][99mTcO4] was eluted from a 99Mo/99mTc-generator (Covidien, Petten) with a 0.9% saline solution.  
Reactions were monitored by HPLC or by thin-layer chromatography (TLC) using precoated silica gel 
60 F254 aluminium sheets (Merck), and visualized by UV absorption or stained with a solution of 
ninhydrin in EtOH.  Column chromatography was performed using silica gel 60 (Fluka; particle size 
0.04-0.063 mm).  Analytical HPLC was performed using a Merck-Hitachi L-7000 system equipped 
with an L-7400 tunable absorption detector and an XBridge™ C-18 reverse phase column (5 µM, 4.6 
x 150 mm, Waters).  HPLC solvents were either water with 0.1% TFA (solvent A) and MeCN 
(solvent B), or water (solvent A) and MeOH (solvent B) (for purification of 99mTc complexes) with a 
flow rate of 1 mL/min.  The gradient was as follows: 0-15 min: gradient from 95% A to 20% A; 15-20 
min: gradient from 20% A to 95% A; 20-25 min 95% A.  Sep-Pak® columns (Waters) were washed 
with methanol and water prior to use.  Products were eluted using water or a water-methanol gradient.  
Nuclear magnetic resonance spectra were recorded on a 400 MHz Bruker spectrometer.  1H and 13C 
chemical shifts are reported relative to residual solvent peaks or water as a reference.  Values of the 
coupling constant, J, are given in Hertz (Hz).  The following abbreviations are used for the description 
of 1H-NMR spectra: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets 
(dd), broad singlet (bs).  The chemical shifts of complex multiplets are given as the range of their 
occurrence.  Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR, with a universal 
ATR sampling accessory.  Low resolution mass spectra were recorded with a Micromass Quattro 
microTM API LC-ESI using either the negative or positive ionization mode.  High resolution mass 
spectra were recorded with a Bruker FTMS 4.7T BioAPEXII. 
125I-IdUrd of high radiochemical purity was prepared from the precursor 5-tri-n-butyl-stannyl-2'-
deoxyuridine and purified by SepPak® RP-18 cartridges using a modified version of a method 
originally described by Foulon et al.(38, 39)  Radiochemical purity was repeatedly verified by TLC 
using polyethyleneimine cellulose F strips (Merck, Darmstadt, Germany) with a mobile phase of 0.2 
M ammonium bicarbonate and radioactivity reading on a Tracemaster 20 (Berthold, Bad Wildbad, 
Germany). In all experiments, 125I-IdUrd represented >98% of overall 125I activity.  Contamination 
with unlabelled IdUrd was avoided in the production of 125I-IdUrd.  It was calculated that the standard 
activity of 5 kBq 125I-IdUrd in 0.5 mL used in the incorporation experiments represented a 
concentration of 0.2 nM, though this is only an indicative value as it has not been experimentally 
verified. 
3',5'-Di-O-(tert-butyl-dimethyl-silanyl)thymidine.  Thymidine (1.00 g, 4.13 mmol) and imidazole 
(1.18 g, 17.34 mmol) were dissolved in DMF (10 mL) and stirred for 5 minutes at room temperature.  
16 
 
TBDMSCl (1.31 g, 8.67 mmol) was added and the reaction stirred at room temperature and followed 
by TLC.  After 16 hours the reaction mixture was diluted with EtOAc (20 mL), and washed twice 
with 1 M NaHCO3, and once with saturated NaCl.  The aqueous phases were re-extracted with 
EtOAc.  The organic phases were combined, dried over Na2SO4 and evaporated under reduced 
pressure to give the product as a colourless liquid (1.90 g, 98%).  1H NMR (CDCl3) δ 8.37 (s, 1H); 
7.45 (d, J = 0.9, 1H); 6.30 (J =7.9, 5.8, 1H); 4.38 (m, 1H); 3.91 (m, J = 2.5, 2.4, 2.4, 1H); 3.84 (dd, J 
= 11.4, 2.5, 1H); 3.74 (dd, J = 11.4, 2.4, 1H); 2.22 (ddd, J = 13.1, 5.8, 2.6, 1H); 2.02-1.89 (m, 1H); 
0.90 (s, 9H); 0.87 (s, 9H); 0.09 (s, 6H); 0.05 (s, 6H) ppm.  13C NMR (CDCl3) δ 163.52, 149.90, 
135.53, 110.64, 87.69, 84.77, 72.21, 62.87, 41.24, 36.36, 31.07, 25.88, 25.68, 12.33, -4.69, -4.89, -
5.34, -5.50 ppm.  High Res. MS (ESI) m/z 471.2706 [C22H42N2O5Si2]H+ (calc. 471.2705). 
3-(2-Bromoethyl)-3',5'-di-O-(tert-butyl-dimethyl-silanyl)thymidine.  3',5'-Di-O-(tert-butyl-
dimethyl-silanyl)-thymidine (1.90 g, 4.04 mmol) was dissolved in DMF (10 mL).  Cs2CO3 (4.40 g, 
12.39 mmol) was added and the mixture was stirred for 5 minutes at room temperature.  
Dibromoethane (7.76 g, 41.28 mmol) was added and the reaction stirred at room temperature and 
followed by TLC.  After 2 hours the reaction mixture was diluted with EtOAc (20 mL), and washed 
twice with 1 M NaHCO3, and once with saturated NaCl.  The aqueous phases were re-extracted with 
EtOAc.  The organic phases were combined, dried over Na2SO4 and evaporated under reduced 
pressure.  The crude product was purified by column chromatography with hexane and EtOAc (20%) 
to give the pure product as a colorless liquid (2.21 g, 95%).  1H-NMR (CDCl3) δ 7.48 (d, 4J(H,H)=1.1, 
1H); 6.36 (m, J =7.9, 5.8, 1H); 4.45-4.29 (m, 3H); 3.95 (m, 1H); 3.87 (dd, J =11.4, J =2.6, 1H); 3.76 
(dd, J =11.4, J =2.4, 1H); 3.54 (t, J =7.2, 2H); 2.30-2.23 (m, 1H); 2.02-1.95 (m, 1H); 1.94 (s, 3H); 
0.93 (s, 9H); 0.90 (s, 9H); 0.12 (s, 6H); 0.09 (s, 3H); 0.08 (s, 3H) ppm.  13C-NMR (CDCl3) δ 162.93, 
150.48, 133.61, 109.88, 87.68, 85.26, 72.22, 62.85, 42.18, 41.41, 29.49, 27.25, 25.93, 25.73, 13.14, -
4.69, -4.87, -5.43, -5.49 ppm.  High Res. MS (ESI) m/z 577.2124 [C24H45BrN2O5Si2]H+ (calc. 
577.2123). 
3-(2-Azidoethyl)-3',5'-di-O-(tert-butyl-dimethyl-silanyl)thymidine, 1a.  3-(2-Bromoethyl)-3′,5′-di-
O-(tert-butyl-dimethyl-silanyl)thymidine (1.03 g, 1.78 mmol) was dissolved in MeCN (20 mL) and 10 
equivalents of NaN3 (1.16 g 17.8 mmol) were added.  The reaction mixture was stirred at 80 °C for 16 
hours and followed by TLC.  After cooling to room temperature the solvent was removed under 
reduced pressure and the product extracted into EtOAc. and washed twice with water and once with 
saturated NaCl.  The aqueous phases were re-extracted with EtOAc.  The organic phases were 
combined, dried over Na2SO4 and evaporated under reduced the pressure to give the pure product as a 
colorless liquid (750 mg, 80%).  1H-NMR (CDCl3) δ 7.48 (d, J = 0.9, 1H); 6.36 (m, J = 7.9, 5.8, 1H); 
4.40 (m, 1H); 4.19 (m, J = 6.3, 1.9, 2H); 3.94 (m, J = 2.4, 1H); 3.87 (dd, J = 11.4, 2.6, 1H); 3.76 (dd, J 
= 11.4, 2.3, 1H); 3.54 (t, J = 6.3, 2H); 2.30-2.23 (m, 1H); 2.02-1.95 (m, 1H); 1.93 (s, 3H); 0.92 (s, 
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9H); 0.89 (s, 9H); 0.19 (s, 6H); 0.08 (s, 3H); 0.07 (s, 3H) ppm.  13C-NMR (CDCl3) δ 163.5, 151.0, 
134.0, 110.1, 88.0, 85.7, 72.4, 63.1, 48.6, 41.6, 40.0, 26.1, 25.9, 18.5, 18.1, 13.2, -4.5, -4.7, -5.2, -5.3 
ppm.  High Res. MS (ESI) m/z 562.2851 [C24H45N5O5Si2]Na+ (calc. 562.2851). 
3-(2-Azidoethyl)thymidine (N3dT-N3), 1.  3-(2-Azidoethyl)-3',5'-di-O-(tert-butyl-dimethyl-
silanyl)thymidine (900 mg, 1.67 mmol) was dissolved in THF (20 mL).  NBu4F (1.16 g, 3.68 mmol) 
was added and the reaction was stirred at room temperature and followed by TLC.  After two hours 
the solvent was removed under reduced pressure and a 1:1 mixture of water and EtOAc (40 mL) was 
added.  The solvent was evaporated from the aqueous phase under reduced pressure and the crude 
product was purified by column chromatography with a mixture of CH2Cl2 and methanol (9%) to give 
the product as a colourless liquid (500 mg, 96%).  1H-NMR (D2O) δ 7.69 (d, J = 1.1, 1H); 6.30 (m, J 
= 6.7, 1H); 4.47 (m, J = 6.4, 4.2, 1H); 4.18 (m, J = 7.0, 5.4, 2H); 4.04 (m, J = 8.7, 3.8, 1H); 3.85 (dd, J 
= 12.5, 5.0, 1H); 3.77 (dd, J = 12.5, 3.6, 1H); 3.56 (t, J = 5.8, 2H); 2.44-2.32 (m, 2H); 1.92 (d, J 
=0.98, 3H).  13C-NMR (CDCl3) δ 166.03, 152.21, 136.44, 111.16, 87.24, 86.61, 71.01, 61.76, 49.50 
(MeOH), 48.90, 40.94, 39.41, 12.88 ppm.  High Res. MS (ESI) m/z 312.1299 [C12H17N5O5]H+ (calc. 
312.1302). 
Alkynes, 2-6.  2-prpargyl glycine, 2, N-Boc-2-prpargyl glycine, 2a, and 2-propargyl dimethyl 
malonate, 4a, are commercially available.  Alkynes 3 and 5 were prepared according to published 
procedures,(14) alkyne 6 was prepared from the reaction of pyridine-2-methylamine (0.53 g, 4.89 
mmol) and propargyl bromide (0.58 g, 4.89 mmol) in a solution of triethylamine (1.02 mL, 7.34 
mmol) in MeCN (50 mL).  The reaction mixture was stirred at 50 °C and followed by TLC.  After 4 
hours the solvent was removed and the reaction mixture purified by column chromatography with 
CH2Cl2 and MeOH (5%).  The product was isolated as a yellow liquid (178 mg, 25%).  Full analytical 
data for compounds 2-6 and 2a-5a can be found in the supporting information.  Data were in 
agreement with those already published.(14) 
Copper catalyzed azide-alkyne cyclycloaddition. General procedure A:  The alkyne (1-2 
equivalents) and azide (1 equivalent) were added to a 1:1 mixture of tBuOH and water to form a 0.1 
mM solution.  0.1 equivalents of Cu(OAc)2.H2O and 0.2 equivalents of sodium ascorbate were added 
and the mixture stirred at room temperature for 12 hours. 
Compound 7.  As per general procedure A, with AZT (130 mg, 0.49 mmol) and 2a (137 mg, 0.64 
mmol).  The solvent was removed and the residue redissolved in a mixture of CH2Cl2 and MeOH 
(10%).  The crude product was purified by column chromatography with a mixture of CH2Cl2 and 
MeOH (10%) to give the Boc protected triazole product (183 mg, 77%).  1H-NMR (CD3OD) δ 7.91 
(s, 1H), 7.89 (s, 1H), 6.49 (t, J = 6.5, 1H), 5.39 (m, 1H), 4.33 (m, 1H), 4.25 (t, J = 5.4, 1H), 3.89 (dd, J 
= 12.2, 2.9, 1H), 3.77 (dd, J = 12.2, 3.1, 1H), 3.24 (dd, J = 14.6, 5.1, 1H), 3.13 (dd, J = 14.6, 6.6, 1H), 
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2.93-2.83 (m, 1H), 2.77-2.64 (m, 1H), 1.91 (s, 3H), 1.41 (s, 9H) ppm.  13C-NMR (CD3OD) δ 166.29, 
152.10, 137.98, 124.35, 111.50, 86.66, 86.40, 80.54, 62.14, 61.07, 38.88, 28.82, 12.51 ppm.  High 
Res. MS (ESI) m/z 481.2039 [C20H28N6O8]H+ (calc. 481.2041).  The intermediate (120 mg, 0.25 
mmol) was dissolved in a mixture of CH2Cl2 (12.5 mL) and TFA (1.25 mL) and stirred overnight at rt.  
The solvent was removed under reduced pressure, and the residue redissolved in water (1 mL) and 
neutralized with 5 M NaOH.  The crude product was purified by solid phase extraction using a Sep-
Pak® column.  The fractions containing the product were evaporated under reduced pressure to give 
12 as a colourless oil (81 mg, 85%).1H-NMR (CDCl3) δ 1H NMR (400 MHz, MeOD) δ 8.01 (s, 1H), 
7.91 (s, 1H), 6.49 (t, J = 6.6, 1H), 5.42 (m, 1H), 4.36 (m, 2H), 3.91 (dd, J = 12.1, 3.0, 1H), 3.78 (dd, J 
= 12.1, 3.2, 1H), 3.43 (dd, J = 15.7, 5.0, 1H), 3.35 (d, J = 15.7, 7.3, 1H), 2.94-2.82 (m, 1H), 2.79-2.65 
(m, 1H), 1.91 (s, 3H) ppm.  13C-NMR (CD3OD) δ 170.88, 166.50, 152.48, 142.79, 138.29, 124.79, 
111.94, 86.90, 86.55, 62.44, 61.49, 53.79, 39.18, 27.32, 12.61 ppm.  High Res. MS (ESI) m/z 
381.1515 [C15H20N6O6]H+ (calc. 381.1517). 
Compound 8.  As per general procedure A, with AZT (100 mg, 0.37 mmol) and 3a (150 mg, 0.70 
mmol).  The solvent was removed and the residue redissolved in a mixture of CH2Cl2 and MeOH 
(10%).  The crude product was purified by column chromatography with a mixture of CH2Cl2 and 
MeOH (10%) to give the Boc protected triazole product (142 mg, 79%).  1H-NMR (CD3OD) δ H 
NMR (400 MHz, MeOD) δ 8.07 (s, 1H), 7.92 (d, J = 0.8, 1H), 6.48 (t, J = 6.4, 1H), 5.41 (dt, J = 8.6, 
5.6, 1H), 4.37 (dt, J = 5.7, 3.0, 1H), 3.91 (dd, J = 12.3, 3.0, 1H), 3.84 (s, 2H), 3.78 (dd, J = 12.3, 3.2, 
1H), 3.21 (t, J = 7.0, 2H), 2.92 (dt, J = 12.5, 6.1, 1H), 2.81-2.65 (m, 1H), 2.58 (t, J = 7.0, 2H), 1.91 (d, 
J = 0.8, 3H), 1.43 (s, 9H). ppm.  13C-NMR (CD3OD) δ 166.29, 152.39, 137.97, 111.50, 102.16, 86.67, 
86.39, 62.12, 60.79, 38.89, 28.72, 12.50 ppm.  High Res. MS (ESI) m/z 483.2018 [C20H30N6O6S]H+ 
(calc. 483.2020).  The intermediate (130 mg, 0.27 mmol) was dissolved in a mixture of CH2Cl2 (13.5 
mL) and TFA (1.35 mL) and stirred overnight at rt.  The solvent was removed under reduced 
pressure, and the residue redissolved in water (1 mL) and neutralized with 5 M NaOH.  The crude 
product was purified by solid phase extraction using a Sep-Pak® column.  The fractions containing 
the product were evaporated under reduced pressure to give 13 as a white powder (77 mg, 74%).1H-
NMR (CD3OD) δ 8.08 (s, 1H), 7.90 (d, J = 0.8, 1H), 6.49 (t, J = 6.5, 1H), 5.42 (dt, J = 8.7, 5.2, 1H), 
4.44-4.28 (m, 1H), 3.90 (dd, J = 12.2, 3.0, 1H), 3.85 (s, 2H), 3.79 (dd, J = 12.2, 3.2, 1H), 2.91 (t, J = 
6.6, 2H), 2.93-2.86 (m, 1H), 2.78-2.72 (m, 1H), 2.69 (t, J = 6.6, 2H), 1.89 (d, J = 0.8, 3H). ppm.  13C-
NMR (CD3OD) δ 167.49, 153.22, 146.98, 138.33, 124.15, 111.92, 86.84, 86.49, 62.41, 61.39, 50.00, 
49.79, 49.58, 49.36, 49.15, 48.94, 48.72, 48.51, 40.92, 39.16, 33.91, 26.14, 12.72 ppm.  High Res MS 
(ESI) m/z 383.1498 [C15H22O4N6S]H+ (calc. 383.1496). 
Compound 9.  As per general procedure A, with AZT (70 mg, 0.26 mmol) and 4a (45 mg, 0.26 
mmol).  The solvent was removed and the residue redissolved in a mixture of CH2Cl2 and MeOH 
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(10%).  The crude product was purified by column chromatography with a mixture of CH2Cl2 and 
MeOH (5%) to give the ester protected triazole product (109 mg, 95%).  1H-NMR (CD3OD) δ 7.90 (s, 
1H), 7.90 (d, J = 1.1, 1H), 6.46 (t, J = 6.5, 1H), 5.38 (dt, J = 8.7, 5.5, 1H), 4.33 (dt, J = 5.9, 3.2, 1H), 
3.92-3.85 (m, 2H), 3.75 (dd, J = 12.2, 3.2, 1H), 3.71 (s, 6H), 3.28 (d, J = 7.6, 2H), 2.88 (ddd, J = 13.9, 
6.6, 5.6, 1H), 2.72 (ddd, J = 14.3, 8.5, 6.3, 1H), 1.91 (d, J = 1.1, 3H). ppm.  13C-NMR (CD3OD) δ 
170.76, 166.69, 152.57, 145.56, 138.53, 124.12, 111.75, 86.89, 86.64, 62.42, 61.14, 53.35, 39.28, 
25.85, 12.65 ppm.  High Res. MS (ESI) m/z 438.1622 [C18H23N5O8]H+ (calc. 438.1619).  The 
intermediate (100 mg, 0.23 mmol) was dissolved in a mixture of MeOH (1 mL) and 1 M NaOH (1 
mL) and stirred for 2 h at rt.  The mixture was neutralized by addition of 1 M HCl, before being 
concentrated under reduced pressure.  The crude product was purified by solid phase extraction using 
a Sep-Pak® column.  The fractions containing the product were evaporated under reduced pressure to 
give 14 as a white solid (90 mg, 85%).  1H-NMR (D2O) δ 7.81 (s, 1H), 7.71 (d, J = 1.1, 1H), 6.42 (dd, 
J = 7.0, 6.0, 1H), 5.35 (dt, J = 8.7, 6.3, 1H), 4.42 (m, 1H), 3.87 (dd, J = 12.8, 3.2, 1H), 3.76 (dd, J = 
12.8, 4.4, 1H), 3.37 (t, J = 7.8, 1H), 3.09 (d, J = 7.8, 2H), 2.95 (ddd, J = 13.0, 6.9, 1H), 2.79 (ddd, J = 
13.0, 8.8, 5.7, 1H), 1.88 (d, J = 1.1, 3H) ppm.  13C-NMR (D2O) δ 177.87, 151.46, 146.98, 137.65, 
122.60, 111.25, 85.47, 84.36, 60.53, 59.25, 58.31, 36.94, 26.39 ppm.  MS (ESI) m/z 408.17 
[C16H18N5O8]-. 
Compound 10.  As per general procedure A, with AZT (200 mg, 0.74 mmol) and 5a (142 mg, 1.12 
mmol).  The solvent was removed and the residue redissolved in a mixture of CH2Cl2 and MeOH 
(10%).  The crude product was purified by column chromatography with a mixture of CH2Cl2 and 
MeOH (10%) to give the ester protected triazole product (140 mg, 48%).  1H-NMR (CD3OD) δ 8.03 
(s, 1H), 7.91 (d, J = 0.9, 1H), 6.48 (t, J = 6.5, 1H), 5.42 (dt, J = 8.6, 5.4, 1H), 4.36 (m, 1H), 3.92 (s, 
2H), 3.90 (dd, J = 12.2, 3.0, 1H), 3.77 (dd, J = 12.2, 3.2, 1H), 3.72 (s, 3H), 3.46 (s, 2H), 2.97-2.83 (m, 
1H), 2.80-2.66 (m, 1H), 1.91 (d, J = 0.9, 3H) ppm.  13C-NMR (CD3OD) δ 173.68, 166.61, 152.50, 
147.09, 138.39, 124.29, 111.82, 86.85, 86.55, 62.29, 61.18, 52.45, 50.19, 44.39, 39.19, 12.62 ppm.  
High Res. MS (ESI) m/z 395.1674 [C16H22N6O6]H+ (calc. 395.1674).  The intermediate (100 mg, 0.25 
mmol) was dissolved in a mixture of H2O (2 mL) and 1 M NaOH (0.5 mL) and stirred for 2 h at rt.  
The mixture was neutralized by addition of 1 M HCl, before being concentrated under reduced 
pressure.  The crude product was purified by solid phase extraction using a Sep-Pak® column.  The 
fractions containing the product were evaporated under reduced pressure to give 15 as a white solid 
(84 mg, 88%).  1H-NMR (D2O) δ 8.26 (s, 1H), 7.69 (s, 1H), 6.41 (t, J = 6.6, 1H), 5.42 (dt, J = 8.7, 5.8, 
1H), 4.44 (dd, J = 9.5, 4.0, 1H), 4.39 (s, 2H), 3.87 (dd, J = 12.7, 3.3, 1H), 3.77 (dd, J = 12.7, 4.3, 1H), 
3.60 (s, 2H), 2.94 (ddd, J = 13.0, 6.6, 1H), 2.80 (ddd, J = 14.7, 8.7, 6.2, 1H), 1.86 (s, 3H). ppm.  13C-
NMR (D2O) δ 171.62, 167.14, 152.22, 138.98, 138.36, 126.49, 112.13, 86.24, 84.89, 61.21, 60.47, 
49.50 (MeOH) 49.12, 41.69, 37.50, 12.15 ppm.  High Res. MS (ESI) m/z 381.1519 [C15H20N6O6]H+ 
(calc. 381.1517). 
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Compound 11.  As per general procedure A, with AZT (85 mg, 0.32 mmol) and 6 (100 mg, 0.68 
mmol).  The product was extracted into EtOAc and washed twice with saturated NaCl.  The aqueous 
phases were re-extracted with EtOAc.  The organic phases were combined, dried over Na2SO4 and 
evaporated under reduced pressure.  The crude product was purified by column chromatography with 
a mixture of CH2Cl2 and MeOH (5%) to give the pure triazole product as a crystalline yellow solid 
(92 mg, 69%).  1H-NMR (CD3OD) δ 8.53 (d, J = 4.5, 1H), 7.96 (s, 1H), 7.86-7.77 (m, 2H), 7.48 (d, J 
= 7.8, 1H), 7.36-7.29 (m, 1H), 6.17 (t, J = 6.6, 1H), 4.69 (t, J = 5.6, 2H), 4.38 (t, J = 5.6, 3H), 3.96 (s, 
4H), 3.87 (q, J = 3.4, 1H), 3.78 (dd, J = 12.0, 3.1, 1H), 3.71 (dd, J = 12.0, 3.7, 1H), 2.26-2.11 (m, 2H), 
1.84 (s, 3H) ppm.  13C-NMR (CD3OD) δ 166.76, 152.71, 138.36, 124.62, 111.90, 86.86, 86.58, 62.43, 
61.46, 39.18, 12.63 ppm.  High Res MS (ESI) m/z [C19H23N7O4]H+. (calc. 414.1890). 
Compound 12.  As per general procedure A, with 1a (487 mg, 0.90 mmol) and 2a (192 mg, 0.90 
mmol).  The product was extracted into EtOAc and washed twice with saturated NaCl.  The aqueous 
phases were re-extracted with EtOAc.  The organic phases were combined, dried over Na2SO4 and 
evaporated under reduced pressure.  The crude product was purified by column chromatography with 
a mixture of CH2Cl2 and MeOH (5%) to give the Boc-protected triazole product as a colourless oil 
(335 mg, 49%).  1H-NMR (CD3OD) δ 7.79 (s, 1H), 7.56 (s, 1H), 6.22 (t, J = 6.7, 1H), 4.85 (s, 4H), 
4.62 (t, J = 5.8, 2H), 4.46 (m, 1H), 4.36 (m, 2H), 4.25 (s, 1H), 3.92 (m, 1H), 3.84 (ddd, J = 23.7, 11.4, 
3.2, 2H), 3.17 (s, 2H), 2.27-2.21 (m, 1H), 2.18–2.02 (m, 1H), 1.87 (s, 4H), 1.42 (s, 9H), 0.94 (s, 9H), 
0.93 (s, 9H), 0.14 (s, 6H), 0.12 (s, 6H) ppm.  13C-NMR (CD3OD) δ 164.99, 152.00, 135.98, 110.61, 
89.33, 87.16, 73.64, 64.16, 42.03, 28.85, 26.55, 26.34, 19.34, 18.92, 13.48, -4.38, -4.55, -5.12, -5.15 
ppm.  MS (ESI) m/z 753.29 [C34H60N6O9Si2]H+.  The intermediate (300 mg, 0.40 mmol) was 
dissolved in MeOH (20 mL).  Concentrated HCl (0.4 mL) was added and the mixture was stirred 
overnight at rt.  The solvent was removed under reduced pressure, and the residue redissolved in a 
mixture of water and EtOAc (1:1, 15 mL).  The aqueous phase was neutralized with 1 M NaOH and 
concentrated under reduced pressure.  The crude product was purified by solid phase extraction using 
a Sep-Pak® column.  The fractions containing the product were evaporated under reduced pressure to 
give 7 as a white powder (95 mg, 56%).1H-NMR (D2O) δ 7.75 (s, 1H), 7.47 (d, J = 0.9, 1H), 6.01 (t, J 
= 6.6, 1H), 4.53 (m, 2H), 4.27 (m, J = 6.4, 4.4, 1H), 4.19 (t, J = 5.4, 2H), 3.85 (m, 2H), 3.67 (dd, J = 
12.5, 3.5, 1H), 3.58 (dd, J = 12.5, 5.1, 1H), 3.18 (dd, J = 15.7, 4.9, 1H), 3.09 (dd, J = 15.7, 7.3, 1H), 
2.26-2.05 (m, 2H), 1.68 (s, 3H).ppm.  13C-NMR (D2O) δ 173.72, 165.71, 151.81, 142.76, 136.62, 
125.91, 110.93, 87.46, 86.68, 70.91, 61.85, 55.14, 49.50 (MeOH), 48.70, 41.81, 39.38, 27.11, 12.70 
ppm.  High Res. MS (ESI) m/z 425.1776 [C17H24N6O7]H+ (calc. 425.1779). 
Compound 13.  As per general procedure A, with 1a (488 mg,  0.90 mmol) and 3a (180 mg, 0.84 
mmol).  The product was extracted into EtOAc and washed twice with saturated NaCl.  The aqueous 
phases were re-extracted with EtOAc.  The organic phases were combined, dried over Na2SO4 and 
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evaporated under reduced pressure.  The crude product was purified by column chromatography with 
a mixture of CH2Cl2 and MeOH (5%) to give the Boc-protected triazole product as a colourless oil 
(240 mg, 38%).  1H-NMR (CDCl3) δ 7.58 (s, 1H), 7.44 (d, J = 1.0, 1H), 6.23 (m, 1H), 4.61 (t, J = 6.0, 
2H), 4.38 (m, 3H), 3.91 (q, J = 2.5, 1H), 3.84 (dd, J = 11.3, 2.5, 2H), 3.77 (s, 2H), 3.73 (dd, J = 11.3, 
2.5, 1H), 3.29 (m, 2H), 2.61 (t, J = 6.6, 2H), 2.24-2.19 (m, 1H), 1.97-192 (m, 1H), 1.86 (d, J = 1.0, 
3H), 1.42 (s, 9H), 0.91 (s, 9H), 0.87 (s, 9H), 0.09 (s, 6H), 0.07 (s, 3H), 0.06 (s, 3H).ppm.  13C-NMR 
(CDCl3) δ 162.96, 150.46, 134.14, 122.15, 109.59, 87.69, 85.28, 71.93, 62.58, 53.51, 47.37, 41.43, 
40.39, 39.32, 31.33, 28.11, 25.90, 25.71, 18.39, 17.95, 13.17, -4.64, -4.90, -5.40, -5.49 ppm.  High 
Res. MS (ESI) m/z 777.3826 [C34H62O7N6S]Na+ (calc. 777.3831).  The intermediate (200 mg, 0.27 
mmol) was dissolved in MeOH (14 mL).  Concentrated HCl (0.28 mL) was added and the mixture 
was stirred overnight at rt.  The solvent was removed under reduced pressure, and the residue 
redissolved in a mixture of water and EtOAc (1:1, 15 mL).  The aqueous phase was neutralized with 1 
M NaOH and concentrated under reduced pressure.  The crude product was purified by solid phase 
extraction using a Sep-Pak® column.  The fractions containing the product were evaporated under 
reduced pressure to give 8 as a colourless oil (100 mg, 89%).1H-NMR (CD3OD) δ 7.92 (s, 1H), 7.83 
(d, J = 0.9, 1H), 6.17 (t, J = 6.6, 1H), 4.68 (t, 2H), 4.45-4.29 (m, 3H), 3.89 (m, 1H), 3.79 (dd, J = 12.0, 
3.1, 1H), 3.76 (s, 2H), 3.72 (dd, J = 12.0, 3.7, 1H), 2.78 (t, J = 6.6, 2H), 2.59 (t, J = 6.6, 2H), 2.27-
2.21 (m, 2H), 2.19-2.12 (m, 2H), 1.86 (d, J = 0.9, 3H) ppm.  13C-NMR (CD3OD) δ 165.18, 152.22, 
146.90, 136.83, 125.10, 110.57, 89.06, 87.35, 72.07, 62.84, 42.01, 41.59, 41.37, 35.27, 25.94, 13.26 
ppm.  High Res. MS (ESI) m/z 427.1755 [C17H26O5N6S]H+ (calc. 427.1758). 
Compound 14.  As per general procedure A, with 1a (200 mg, 0.37 mmol) and 4a (63 mg, 0.37 
mmol).  The product was extracted into EtOAc and washed twice with saturated NaCl.  The aqueous 
phases were re-extracted with EtOAc.  The organic phases were combined, dried over Na2SO4 and 
evaporated under reduced pressure.  The crude product was purified by column chromatography with 
a mixture of CH2Cl2 and MeOH (3%) to give the TBDMS and ester protected triazole product (194 
mg, 74%).  1H-NMR (CD3OD) δ 7.43 (s, 1H), 6.24 (dd, J = 7.8, 5.8, 1H), 4.56 (t, J = 6.3, 2H), 4.37 
(dd, J = 7.6, 4.9, 3H), 3.91 (q, J = 2.5, 1H), 3.84 (dt, J = 5.8, 5.1, 2H), 3.75 (t, J = 2.2, 1H), 3.72 (s, 
7H), 3.28 (d, J = 7.6, 2H), 2.22 (ddd, J = 13.2, 5.8, 2.7, 1H), 1.95 (ddd, J = 13.2, 7.8, 6.1, 1H), 1.87 
(d, J = 1.1, 3H), 0.91 (s, 9H), 0.88 (s, 9H), 0.09 (s, 6H), 0.06 (d, J = 3.8, 6H) ppm.  13C-NMR 
(CD3OD) δ 168.87, 162.94, 150.46, 143.77, 133.89, 122.44, 109.86, 87.69, 85.26, 71.93, 62.86, 52.46, 
51.09, 47.38, 41.25, 25.78, 25.69, 24.70, 18.26, 17.69, 12.92, -4.99, -5.79 ppm.  High Res. MS (ESI) 
m/z 732.3428 [C32H55N5O9Si2]Na+ (calc. 732.3431).  The intermediate (190 mg, 0.27 mmol) was 
dissolved in MeOH (15 mL).  Concentrated HCl (0.3 mL) was added and the mixture was stirred 
overnight at rt.  The solvent was removed under reduced pressure, and the residue redissolved in a 
mixture of water and EtOAc (1:1, 15 mL).  The pH of the aqueous phase was increased to 12 with 1 
M NaOH and stirred for a further 2 h at rt.  After this time the mixture was neutralized with 1 M HCl 
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before the solvent was removed under reduced pressure.  The crude product was purified by solid 
phase extraction using a Sep-Pak® column.  The fractions containing the product were evaporated 
under reduced pressure to give 9 as a white powder (86 mg, 70%).  1H-NMR (CD3OD) δ 7.69 (s, 1H), 
7.61 (s, 1H), 6.13 (t, J = 6.5, 1H), 4.64 (m, 2H), 4.42 (dt, J = 6.4, 4.2, 1H), 4.34 (m, 2H), 4.05-3.94 
(m, 1H), 3.82 (dd, J = 12.5, 3.5, 1H), 3.73 (dd, J = 12.5, 5.2, 1H), 3.35 (t, J = 7.8, 1H), 3.06 (d, J = 
7.8, 2H), 2.40-2.17 (m, 2H), 1.84 (s, 3H) ppm.  13C NMR (D2O) δ 146.94, 136.31, 124.25, 110.63, 
87.10, 86.74, 70.80, 61.67, 49.50 (MeOH) 39.35, 12.67.  High Res. MS (ESI) m/z 476.1378 
[C18H23N5O9]Na+ (calc. 476.1388). 
Compound 15.  As per general procedure A, with 1 (144 mg, 0.46 mmol) and 5a (59 mg, 0.46 
mmol).  The solvent was removed and the residue redissolved in a mixture of CH2Cl2 and MeOH 
(10%).  The crude product was purified by column chromatography with a mixture of CH2Cl2 and 
MeOH (10%) to give the ester protected triazole product (135 mg, 67%).  1H-NMR (CD3OD) δ 7.90 
(s, 1H), 7.83 (d, J = 1.0, 1H), 6.17 (t, J = 6.6, 1H), 4.68 (t, J = 5.7, 2H), 4.37 (t, J = 5.6, 3H), 3.92-3.85 
(m, 3H), 3.80 (dd, J = 12.0, 3.1, 1H), 3.74-3.70 (dd, J = 12.0, 3.8, 1H), 3.72 (s, 3H), 2.24 (ddd, J = 
13.6, 6.2, 3.9, 1H), 2.16 (ddd, J = 11.4, 6.6, 1H), 1.85 (d, J = 1.0, 3H) ppm.  13C-NMR (CD3OD) δ 
165.08, 152.25, 136.76, 125.04, 110.37, 88.96, 87.10, 71.92, 62.57, 43.87, 42.08, 41.54, 13.13 ppm.  
High Res. MS (ESI) m/z 439.1933 [C18H26N6O7]H+ (calc. 439.1936).  The intermediate (112 mg, 0.26 
mmol) was dissolved in a mixture of H2O (2 mL) and 1 M NaOH (0.5 mL) and stirred for 2 h at rt.  
The mixture was neutralized by addition of 1 M HCl, before being concentrated under reduced 
pressure.  The crude product was purified by solid phase extraction using a Sep-Pak® column.  The 
fractions containing the product were evaporated under reduced pressure to give 10 as a white solid 
(70 mg, 61%).  1H-NMR (CD3OD) δ 7.97 (s, 1H), 7.82 (s, 1H), 6.16 (t, J = 6.6, 1H), 4.68 (t, J = 5.6, 
2H), 4.37 (m, 3H), 3.98 (s, 2H), 3.90 (q, J = 3.4, 1H), 3.79 (dd, J = 12.0, 3.1, 1H), 3.72 (dd, J = 12.0, 
3.8, 1H), 3.31 (s, 2H), 2.25 (ddd, J = 13.5, 6.1, 3.8, 1H), 2.15 (ddd, J = 13.5, 6.6, 1H), 1.86 (s, 3H) 
ppm.  13C-NMR (CD3OD) δ 176.69, 165.06, 152.03, 145.19, 136.79, 125.45, 110.43, 88.81, 87.25, 
71.77, 62.64, 52.00, 43.92, 41.88, 41.34, 13.07 ppm.  High Res. MS (ESI) m/z 425.1776 
[C17H24N6O7]H+ (calc. 425.1779). 
Compound 16.  As per general procedure A, with 1 (280 mg, 0.90 mmol) and 6 (131 mg, 0.88 
mmol).  The product was extracted into EtOAc and washed twice with saturated NaCl.  The aqueous 
phases were re-extracted with EtOAc.  The organic phases were combined, dried over Na2SO4 and 
evaporated under reduced pressure.  The crude product was purified by column chromatography with 
a mixture of CH2Cl2 and MeOH (5%) to give the pure triazole product as a yellow solid (220 mg, 
55%).1H-NMR (CD3OD) δ 8.53 (d, J = 4.5, 1H), 7.96 (s, 1H), 7.86-7.77 (m, 2H), 7.48 (d, J = 7.8, 
1H), 7.33 (m, 1H), 6.17 (t, J = 6.6, 1H), 4.69 (t, J = 5.6, 2H), 4.38 (t, J = 5.6, 2H), 4.37 (m, 1H), 3.96 
(s, 4H), 3.87 (q, J = 3.4, 1H), 3.78 (dd, J = 12.0, 3.1, 1H), 3.71 (dd, J = 12.0, 3.7, 1H), 2.26-2.11 (m, 
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2H), 1.84 (s, 3H) ppm.  13C-NMR (CD3OD) δ 165.20, 159.35, 152.25, 150.18, 146.37, 138.93, 
136.91, 125.44, 124.40, 124.12, 110.58, 89.06, 87.36, 72.07, 62.84, 53.95, 44.26, 42.13, 41.52, 18.52, 
13.22 ppm.  High Res. MS (ESI) m/z 458.2149 [C21H27N7O5]H+ (calc. 458.2146). 
Rhenium complexes.  Tricarbonyl rhenium complexes were synthesized according to the following 
general procedure: One equivalent of thymidine containing ligand and one equivalent of 
[ReBr3(CO)3][NEt4]2were dissolved in a 1:1 mixture of MeOH and water to form a 0.1 M solution.  In 
the reactions with ligands 9 and 14 the pH of the reaction mixture was adjusted to 7 with aqueous 
NEt4OH.  The reaction was stirred at 50 °C for 2 h and followed by HPLC.  The solvents were 
removed under vacuum and the residue was purified by solid phase extraction using a Sep-Pak® 
column and a water-MeOH gradient to give the Re(CO)3 complex as a white or off-white powder. 
[Re(CO)37]. (41 mg, 59%).  1H-NMR (CD3OD) δ 8.20 (s, 1H), 7.86 (s, 1H), 6.44 (t, J = 6.4, 1H), 5.90 
(dd, J = 11.0, 5.8, 1H), 5.58-5.44 (m, 1H), 5.18 (d, J = 11.4, 1H), 4.45-4.32 (m, 1H), 4.11 (d, J = 3.9, 
1H), 3.92 (dd, J = 12.2, 2.9, 1H), 3.81 (dd, J = 12.2, 3.1, 1H), 3.38 (dd, J = 16.0, 1H), 3.26 (dd, J = 
4.2, 1H), 3.02-2.73 (m, 2H), 1.91 (s, 3H) ppm.  13C-NMR (CD3OD) δ 197.39, 196.67, 184.57, 166.45, 
152.22, 144.06, 138.43, 126.48, 111.81, 86.97, 85.89, 62.30, 62.01, 52.78, 38.68, 27.39, 12.19 ppm.  
High Res MS (ESI) m/z 651.0846 [C18H19N6O9Re]H+ (calc. 651.0844). 
[Re(CO)38]Br. (17 mg, 61%).  1H-NMR (CD3OD) δ 8.41 (s, 1H), 7.88 (s, 1H), 6.48 (t, J = 6.3, 1H), 
5.55 (m, 1H), 5.32 (bs, 1H), 4.60 (bs, 1H), 4.53 (d, J = 17.2, 1H), 4.56-4.47 (m, 1H), 4.24 (d, J = 17.2, 
1H), 3.93 (dd, J = 12.0, 3.1, 1H), 3.86 (dd, J = 12.0, 1H), 3.04-2.96 (m, 1H), 2.95-2.87 (m, 1H), 2.92 
(m, 2H), 2.86-2.74 (m, 1H), 2.27 (m, 1H) ppm.  13C-NMR (CD3OD) δ 166.42, 152.40, 151.52, 
138.40, 125.44, 111.65, 87.03, 86.92, 86.23, 85.88, 63.81, 63.66, 62.60, 62.37, 44.65, 39.03, 34.23, 
12.61 ppm.  High Res. MS (ESI) m/z 653.0818 [C18H22N6O7ReS]+ (calc. 653.0822). 
[Re(CO)39]NEt4. (30 mg, 45%).  1H-NMR (CD3OD) δ 8.20 (s, 1H), 7.89 (d, J = 1.1, 1H), 6.46 (t, J = 
6.4, 1H), 5.57-5.47 (m, 1H), 4.43 (dt, J = 6.1, 3.2, 1H), 3.95 (dd, J = 12.4, 3.0, 1H), 3.85 (dd, J = 12.4, 
3.3, 1H), 3.61 (t, J = 4.7, 1H), 3.44 (d, J = 4.7, 2H), 3.37-3.28 (m, 8H), 3.06-2.93 (m, 1H), 2.84 (ddd, 
J = 14.3, 8.7, 5.8, 1H), 1.93 (d, J = 1.1, 3H), 1.35-1.27 (m, 12H) ppm.  13C-NMR (CD3OD) δ 198.32, 
179.91, 179.88, 166.42, 152.23, 147.36, 138.48, 126.96, 111.65, 86.92, 86.10, 62.05, 62.03, 53.82, 
53.31, 53.28, 53.25, 38.79, 27.02, 12.46, 7.59 ppm.  High Res. MS (ESI) m/z 680.00629 
[C19H19N5O11Re]+ (calc. 680.0634). 
[Re(CO)310]. (58 mg, 83%).  1H-NMR (CD3OD) δ 1H NMR (400 MHz, MeOD) δ 8.32 (s, 1H), 7.86 
(d, J = 5.6, 1H), 6.46 (q, J = 6.8, 1H), 5.62-5.47 (m, 1H), 4.40 (dd, J = 5.2, 3.2, 1H), 4.36-4.22 (m, 
2H), 3.88 (dd, 1H), 3.83-3.77 (m, 1H), 3.81 (d, J = 17.3, 1H), 3.38 (d, J = 17.3, 1H), 3.04-2.93 (m, 
1H), 2.85-2.76 (m, 1H), 1.91 (s, 3H) ppm.  13C-NMR (CD3OD) δ 197.37, 196.71, 183.78, 166.35, 
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152.20, 149.87, 138.37, 124.04, 111.79, 86.68, 85.88, 62.93, 61.86, 56.29, 53.09, 38.38, 12.50 ppm.  
High Res MS (ESI) m/z 651.0838 [C18H19N6O9Re]H+ (calc. 651.0844). 
[Re(CO)311]Br. (64 mg, 55%).  1H-NMR (CD3OD) δ 1H NMR (400 MHz, MeOD) δ 8.83 (t, J = 5.9, 
1H), 8.15 (s, 1H, isomer A), 8.14 (s, 1H, isomer B), 8.00-7.91 (m, 1H), 7.82 (s, 1H), 7.60 (d, J = 7.9, 
1H), 7.39 (dd, J = 13.2, 6.6, 1H), 6.38 (td, J = 6.6, 2.2, 1H), 5.40 (dt, J = 9.4, 4.9, 1H), 4.78 (d, J = 
17.0, 1H), 4.69 (d, J = 17.0, 1H), 4.52 (d, J = 16.5, 1H), 4.40-4.31 (m, 1H, isomer B), 4.36 (d, J = 
16.5, 1H), 4.17-4.05 (m, 1H, isomer A), 3.84 (dd, J = 12.1, 3.3, 1H, isomer B), 3.79 (dd, J = 12.2, 3.3, 
1H, isomer A), 3.70 (dd, J = 12.1, 3.1, 1H, isomer B), 3.60 (dd, J = 12.2, 3.2, 1H, isomer A), 2.90-
2.80 (m, 1H, isomer A), 2.72 (ddd, J = 14.4, 8.3, 6.4, 1H, isomer A), 2.63 (dd, J = 14.0, 7.2, 1H, 
isomer B), 2.48 (ddd, J = 14.1, 6.4, 4.8, 1H, isomer B), 1.90 (s, 3H) ppm.  13C-NMR (CD3OD) δ 
166.27, 161.70, 153.16, 151.89, 150.24, 140.91, 137.97, 126.77, 124.37, 124.07, 111.80, 86.69, 86.48, 
85.91, 85.65, 63.87, 63.45, 63.15, 62.27, 62.00, 52.77, 39.16, 38.39, 12.19 ppm.  High Res MS (ESI) 
m/z 684.1214 [C22H23N7O7Re]+ (calc. 684.1212). 
[Re(CO)312]. (55 mg, 95%).  1H-NMR (CD3OD) δ 8.08 (s, 1H), 7.85 (s, 1H), 6.20 (t, J = 6.6, 1H), 
5.91-5.77 (m, 1H), 5.15 (d, J = 11.2, 1H), 4.78 (m, 2H), 4.48-4.34 (m, 2H), 4.08 (m, 1H), 3.92 (m, J = 
3.3, 1H), 3.80 (dd, J = 12.0, 3.0, 1H), 3.73 (dd, J = 12.0, 3.8, 1H), 3.38 (m, 1H), 3.27 (dd, J = 17.6, 
4.3, 1H), 2.39 (ddd, J = 13.6, 5.9, 3.6, 1H), 2.24-2.18 (m, 1H), 1.89 (s, 3H) ppm.  13C-NMR (DMSO) 
δ 198.26, 197.44, 196.44, 180.16, 162.49, 150.18, 142.22, 135.08, 126.16, 108.26, 87.38, 84.99, 
69.95, 61.07, 50.69, 50.60, 48.57, 48.05, 25.97, 12.84 ppm.  High Res MS (ESI) m/z 695.1106 
[C20H23N6O10Re]H+ (calc. 695.1107). 
[Re(CO)313]Br. (20 mg, 74%).  1H-NMR (CD3OD) δ 8.26 (s, 1H), 8.22 (s, 1H), 7.88 (d, J = 0.9, 1H), 
7.87 (d, J = 0.9, 1H), 6.27-6.22 (m, 1H), 6.21 (t, J = 6.5, 1H), 5.43 (bs, 1H), 5.37 (bs, 1H), 4.87-4.79 
(m, 2H), 4.79-4.69 (m, 2H), 4.55-4.47 (m, 2H), 4.47-4.42 (m, 2H), 4.43-4.36 (m, 2H), 4.34 (dd, J = 
7.6, 4.5, 1H), 4.30 (d, J = 3.5, 1H), 4.20 (d, J = 11.3, 1H), 4.16 (d, J = 11.2, 1H), 4.10 (bs, 2H), 3.93 
(dd, J = 6.6, 3.3, 1H), 3.91 (dd, J = 6.7, 3.4, 1H), 3.81 (t, J = 2.8, 1H), 3.78 (t, J = 2.7, 1H), 3.76-3.72 
(m, 1H), 3.72-3.68 (m, 1H), 3.05-2.88 (m, 3H), 2.88-2.76 (m, 2H), 2.76-2.61 (m, 1H), 2.47 (m, 1H), 
2.41-2.29 (m, 1H), 2.27-2.19 (m, 4H), 1.88 (s, 3H), 1.87 (s, 3H) ppm.  13C-NMR (CD3OD) δ 165.44 
(165.29), 152.51, 151.23 (150.97), 137.22 (137.04), 126.03 (125.90), 110.87, 89.10, 87.02, 72.50 
(72.37), 63.06 (62.99), 51.44 (51.32), 44.90 (44.38), 42.82 (42.65), 41.14 (41.06), 38.92 (38.59), 
34.38 (34.27), 13.11 ppm.  High Res MS (ESI) m/z 697.1086 [C20H26N6O8ReS]+ (calc. 697.1084). 
[Re(CO)314]NEt4. (67 mg, 65%).  1H-NMR (CD3OD) δ 8.06 (s, 1H), 7.76 (d, J = 1.0, 1H), 6.04 (t, J = 
6.4, 1H), 4.79-4.68 (m, 2H), 4.51-4.42 (m, 1H), 4.40-4.34 (m, 2H), 3.88 (m, 1H), 3.78 (dd, J = 12.1, 
3.3, 1H), 3.70 (dd, J = 12.1, 4.3, 1H), 3.56 (t, J = 4.3, 1H), 3.39 (d, J = 4.3, 2H), 3.34-3.25 (m, 8H), 
2.28 (ddd, J = 13.8, 6.3, 4.0, 1H), 2.14-2.05 (m, 1H), 1.87 (d, J = 0.9, 3H), 1.33-1.25 (m, 12H) ppm.  
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13C-NMR (CD3OD) δ 164.66, 152.10, 147.03, 137.40, 128.06, 88.54, 87.76, 71.76, 62.64, 53.08, 
41.86, 41.31, 12.99, 7.42 ppm.  High Res. MS (ESI) m/z 721.90 [C21H21N5O12Re]- (calc. ). 
[Re(CO)315]. (96 mg, 84%).  1H-NMR (CD3OD) δ 8.18 (s, 1H), 7.84 (m, 1H), 7.23-7.12 (m, 1H), 
6.26 (m, 1H), 4.81-4.69 (m, 2H), 4.55-4.28 (m, 3H), 3.91 (m, 1H), 3.84-3.68 (m, 3H), 3.35-3.30 (m, 
2H), 2.42-2.26 (m, 1H), 2.21 (m, 1H), 1.92-1.84 (m, 3H) ppm.  13C-NMR (CD3OD) δ 183.90, 165.23, 
151.88, 149.46, 136.63, 124.91, 110.45, 88.82, 87.25, 86.96, 71.99, 62.64, 55.73, 53.58, 41.28, 12.98 
ppm.  High Res MS (ESI) m/z 695.1117 [C20H23N6O10Re]H+ (calc. 695.1107). 
[Re(CO)316]Br. (110 mg, 73%).  1H-NMR (CD3OD) δ 8.77 (t, J = 5.0, 1H), 8.01-7.93 (m, 2H), 7.97 
(s, 1H), 7.84 (d, 1H), 7.63 (d, J = 8.0, 1H), 7.38 (t, J = 6.6, 1H), 6.12 (t, J = 6.8, 1H), 4.80-4.55 (m, 
4H), 4.49 (dd, J = 16.7, 8.1, 1H), 4.41 (dt, J = 6.1, 3.2, 1H), 4.37-4.21 (m, 3H), 3.99-3.92 (m, 1H), 
3.81 (dd, J = 12.0, 3.1, 2H), 3.74 (dd, J = 12.0, 3.7, 2H), 2.28-2.12 (m, 2H), 1.84 (d, 3H) ppm.  13C-
NMR (CD3OD) δ 164.98 (164.96), 161.85 (161.79), 153.48 (153.46), 152.12 (152.02), 150.64 
(150.61), 141.48 (141.45), 136.86, 126.66, 124.57 (124.55), 124.49 (124.43), 110.58 (110.53), 89.10 
(89.07), 87.08 (86.92), 72.33 (72.31), 63.96, 62.93 (62.91), 53.13 (53.07), 50.79 (50.56), 41.87 
(41.67), 41.27 (41.19), 13.17 ppm.  High Res MS (ESI) m/z 728.1470 [C24H27N7O8Re]+ (calc. 
728.1474). 
Technetium-99m complexes.  The 99m-technetium tricarbonyl complexes of ligands 7, 8, 10, 11, 12, 
13, 15 and 16, were synthesized according to the following general procedure: A solution of 
[99mTc(CO)3(H2O)3]+ (50 µL; ~500 MBq mL-1) was added to a 10-3 M solution of the relevant ligand 
(50 µL) diluted with PBS (400 µL; pH 7.4) to give a final ligand concentration of 10-4 M.  The 
reaction mixtures were heated for 45 min at 95 °C.  The radioactive product was separated from 
unlabelled ligand by HPLC.  The complexes were characterized by comparison of their HPLC 
retention times (γ-trace) with those of their rhenium analogues (UV-trace). 
 
X-ray crystallography 
Crystallographic data were collected at 183(2) K on an Oxford Diffraction Xcalibur system with a 
Ruby detector (Mo Kα radiation, λ = 0.7107 Å) using graphite-monochromated radiation.  A suitable 
crystal was covered with oil (Infineum V8512, formerly known as Paratone N), mounted on top of a 
glass fiber and immediately transferred to the diffractometer.  The program suite CrysAlisPro was used 
for data collection, semi-empirical absorption correction and data reduction.(40)  The structure was 
solved with direct methods using SIR97(41) and refined by full-matrix least-squares methods on F2 
with SHELXL-97.(42)  The final model was checked with the help of the program Platon.(43)  
26 
 
CCDC-743723 contains the supplementary crystallographic data for this paper.  This data is presented 
in the supporting information or can be obtained free of charge from The Cambridge Crystallographic 
Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
In vitro analysis 
Phosphorylation transfer assays.  Thymidine and thymidine analogues [Re(CO)37-16]0/+/- were 
assayed at 25 °C for 15 minutes in 200 µL of a mixture containing 155.38 µL water, 10 µL 1 M 
HEPES buffer (pH 7.5), 0.2 µL 1 M DTT, 0.42 µL 100 mM PEP, 0.5 µL 1 M MgCl2, 7.2 µL 5 mM 
NADH, 2 µL 100 mM ATP, 0.6 µL pyruvate kinase (1350 U/mL), 0.7 µL lactate dehydrogenase 
(1420 U/mL), 5 µL hTK1 (~0.5 mg/mL) and 20 µL of a 10 mM solution of thymidine or the 
thymidine analogue [Re(CO)37-16]0/+/-. 
For each substrate the linear decrease in UV absorption at 340 nm was measured from 0 to 15 
minutes. The gradients of the regression lines between 6 and 12 minutes were compared to thymidine, 
the phosphorylation of which was assumed to be 100%. 
Thymidine analogues [Re(CO)3X]0/+ (X = 7, 10, 11, 15) were also assayed at 37 °C for 1 hour in 200 
µL of a mixture containing 112.3 µL water, 10 µL 1 M HEPES buffer (pH 7.5), 0.2 µL 1 M DTT, 0.5 
µL 1 M MgCl2, 2 µL 100 mM ATP, 5 µL hTK1 (~0.5 mg/mL), 20 µL of a 10 mM solution of 
[Re(CO)3X]0/+ (X = 7, 10, 11, 15) and 50 µL of an aqueous solution of [99mTc(CO)3X]0/+ (X = 7, 10, 
11, 15) (~100 kBq).  The reaction mixtures were quenched by addition of 800 µL 5 mM EDTA 
solution and analyzed by HPLC. 
Cell lines and culture.  Two human glioblastoma cell lines were used: U251 (American Type Culture 
Collection, ATCC) and LN229 (a gift from Prof. N. de Tribolet, Service of Neurosurgery, University 
Hospital, Geneva, Switzerland).  Cells were cultured at 37 °C and 5% CO2 in RPMI 1640 with 
glutamax I (Invitrogen AG, Basel Switzerland), supplemented with 10% heat-inactivated fetal bovine 
serum (Chemie Brunschwig AG, Basel, Switzerland), penicillin (50 units/ml) and streptomycin (0.05 
mg/mL; Life Technologies Inc., Grand Island, NY, USA), which was changed twice a week.  Because 
mycoplasma contamination is a potential source of increased nucleoside turnover and could therefore 
modulate FdUrd efficacy, the cell lines were regularly tested for four major potential mycoplasma 
contaminations (Mycoplasma Detection Kit, F. Hoffmann-La Roche Ltd, Basel, Switzerland). 
Radioactive dT analogue incorporation assay.  24-well culture dishes were plated with 20,000 cells 
for LN229 and with 15,000 cells for U251.  After 3 days, the exponentially growing cells were 
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incubated for 2 h at 37 °C and 5% CO2 with either 5 kBq 125I-IdUrd, 10 kBq [99mTc(CO)37], or 10 kBq 
[99mTc(CO)316]+ in 0.5 mL medium.  After this time the supernatant was removed and the cells were 
washed three times with PBS.  The cells were detached with 300 μL of 1 M NaOH.  Radioactivity 
was measured in a gamma counter (Wizard 3” 1480 automatic gamma counter, Wallac Oy, Turku, 
Finland) and the results expressed as a percentage of the initial activity added.  In the FdUrd pre-
treatment assay, cells were pre-treated with 1 µM FdUrd and incubated for 1 hour at 37 °C and 5% 
CO2.  After this time the supernatant was removed and the cells were washed twice with PBS before 
either 5 kBq 125I-IdUrd, 10 kBq [99mTc(CO)37], or 10 kBq [99mTc(CO)316]+ was added in 0.5 mL fresh 
medium. 
Supporting Information Available: NMR and HPLC analysis of target complexes, crystal data and 
structure refinement for [Re(CO)311][CF3CO2]0.8[Br]0.2, and further details of the phosphorylation 
assay.  This material is available free of charge via the Internet at http://pubs.acs.org. 
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